DPP4 and metabolic dysfunction-associated steatohepatitis: In mouse models of NASH-related HCC, dipeptidyl peptidase-4 inhibitor (DPP4i) inhibits the p62/Keap1/Nrf2 pathway to downregulate the PPP pathway, thereby halting the progression of NASH-related HCC (161).